Tissue Phenomics™ is the big data approach to biomarker discovery and clinical diagnostic assay development in oncology. Through the utilization of the revolutionary Cognition Network Technology®, invented by Nobel Laureate and Definiens founder, Dr. Gerd Binnig, Tissue Phenomics™ enables the datafication of tissue images for robust data mining and correlation of tissue structures and cells with genomic data and patient demographics. The end result is:
- The discovery, development, and validation of better biomarkers for companion diagnostics in cancer
- The design and implementation of smaller, more conclusive clinical trials that demonstrate medical value of cancer treatments
- The improvement of sample selection for molecular diagnostic tests for greater test sensitivity
In this webinar, Dr. Thomas Nifong, Executive Vice President of Diagnostic Tests at Definiens, will be providing an overview of Tissue Phenomics™ and how the platform supports improved biomarker discovery on through to clinical diagnostic assay commercialization. He will then spend time walking through real-world examples that demonstrate the impact of Tissue Phenomics™ in discovery, clinical trials, and clinical diagnostics development and commercialization.
Thomas Nifong, MD, Executive Vice President, Diagnostic Tests, Definiens
Dr. Nifong has more than 15 years of experience in clinical diagnostics development and operations, laboratory medicine, and project engineering. Prior to joining Definiens, Dr. Nifong was Senior Vice President of Clinical Operations for Metamark Genetics, where he successfully led efforts to translate quantitative multiplex immunofluorescence research protocols into robust, reproducible laboratory developed tests (LDTs) for clinical use. He spent 10 years as a faculty member at the Penn State Hershey Medical Center where he gained extensive experience in molecular pathology, clinical laboratory medicine, and laboratory validation and management.
Dr. Nifong holds a BS in Chemical Engineering from Purdue University and an MD from the University of Rochester. He completed his residency training in Clinical Pathology and is a Diplomat of the American Board of Pathology and a Fellow of the American Society for Clinical Pathology and the College of American Pathologists.Message Presenter
Who Should Attend?
This webinar will be ideal for Pharmaceutical, Biotech and Diagnostics executives from vice presidents up through Chief Scientific, Medical and Executive Officers, lab and study directors, and medical directors.
Definiens is the global leader in Tissue Phenomics™ for discovery and diagnostics development in oncology and provides image analysis solutions for life sciences. Definiens’ technology provides detailed tissue biomarker readouts from slide images and enables the correlation of this information with other key clinical or genomic information, an approach known as Tissue Phenomics™. Definiens helps Pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy.
Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine, and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany and has its North American headquarters in Carlsbad, CA. Further information is available at www.definiens.com.